Kineta, Inc. (KANT) Stock
KANT is no longer traded. Kineta was delisted from the Nasdaq in June 2025.
Prices on this page are historical; the last trade was June 27, 2025 at $0.34.
Kineta stock price history
KANT final trading statistics
- Final close
- $0.34
- Final trading day
- Jun 27, 2025
- Market cap at delisting
- $4.12M
- Shares outstanding
- 12.27M
- Final 52-week range
- $0.18 – $1.15
- Avg. volume (final 3 mo.)
- 15,614
- All-time high (split-adj.)
- $8.33 · Feb 2023
- All-time low (split-adj.)
- $0.09 · Aug 2019
- Return since IPO
- -64.6%
- Beta
- -3.66
- Book value / share
- -$0.79
- Price / book
- -0.42
Kineta annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $5.44M | -$14.1M | -$1.54 |
| FY2022 | $1.04M | -$63.4M | — |
| FY2021 | $9.09M | -$11.8M | — |
| FY2020 | $10.49M | -$8.1M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. It has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., Merck &Co., Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Mercer Island, Washington.
Kineta stock FAQ
What happened to Kineta stock?
Kineta stock was delisted from the Nasdaq. Its final close was $0.34 on June 27, 2025.
Is KANT stock still trading?
No. KANT was delisted from the Nasdaq in June 2025 and no longer trades on a U.S. exchange.
What was the last price of KANT stock?
KANT closed at $0.34 on its final trading day, June 27, 2025, for a market value of about $4.12M.
What were Kineta's revenue and earnings in its last full fiscal year?
Kineta reported revenue of $5.44M and net income of -$14.1M in fiscal 2023, its last full year as a public company.
When did Kineta go public?
Kineta, Inc. stock began trading on February 11, 2016.